News
How does empagliflozin perform in older type 2 diabetics compared to liraglutide and sitagliptin in terms of HHF and MACE risks?
Last fall, a study was published in JAMA Network Open, focusing on older patients with type 2 diabetes mellitus (DM2), examining the cardiovascular risk impact when treated with empagliflozin, liraglutide, or sitagliptin. Currently, there is limited evidence comparing the effectiveness of various glucose-lowering agents intended for second-line treatment in DM2 patients undergoing routine care, who have a broad spectrum of cardiorenal risks.
Prof. Roman Chlíbek: Role of Multivalent Pneumococcal Conjugate Vaccines in Healthy and Premature Children
Children are frequent carriers of pneumococci, which can cause both common non-invasive and more…
Hereditary Angioedema as a Clinical Picture of Excessive Activation of the Kinin Cascade – Case Report
Painful and potentially life-threatening swellings are characteristic of hereditary angioedema…
Efficacy of Empagliflozin in HFpEF Patients – Comparison of Subpopulations with Preserved and Mid-Range LV EF
A sub-analysis of the EMPEROR-Preserved clinical trial examined the effects and safety of…
EULAR 2023: How does tofacitinib affect cardiovascular risk in rheumatoid arthritis?
At this year's European League Against Rheumatism (EULAR) congress, held at the turn of May and…
Efficacy of Ceftazidime/Avibactam in the Treatment of Infections Caused by Carbapenemase-Producing Enterobacteria
Infections caused by carbapenemase-producing enterobacteria are associated with high mortality, and…
EULAR 2023: What Do CRP Levels Reveal About the Efficacy and Safety of Tofacitinib in Patients with Ankylosing Spondylitis?
What is the impact of baseline C-reactive protein (CRP) levels on the efficacy and safety of…
Long-term treatment of ozanimod in patients with moderate to severe ulcerative colitis
The immunosuppressive ozanimod was approved for the treatment of ulcerative colitis (UC) based on…
Can SGLT2 Inhibition Also Reduce the Risk of Nephrolithiasis?
Diabetes mellitus (DM) is a risk factor for the development of nephrolithiasis. Recent studies…
MS in the Digital Age: Doctor as a Lifebuoy in the Sea of Information
How to offer a helping hand to patients amidst the flood of information and why is communication…